Table 1.
ESC/EAS European Society of Cardiology/European Atherosclerosis Society, SCORE Systemic Coronary Risk Estimation, ACC/AHA American Cardiology Association/American Heart Association, PCE Pooled Cohort Equation, CCS Canadian Cardiovascular Society, FRS-CVD Framingham Risk Score of Cardiovascular Disease, USPSTF United States Preventative Services Task Force, NICE-UK National Institute for Health and Care Excellence, United Kingdom, CAC coronary artery calcium, VA/DoD Veterans Affairs/Department of Defense, LDL-C low-density lipoprotein-cholesterol, FRE Framingham Risk Estimator, AHA American Heart Association, ACC American College of Cardiology, AACVPR American Association of Cardiovascular and Pulmonary Rehabilitation, AAPA American Association Academy of Physician Assistants, ABC Association of Black Cardiologists, ACPM American College of Preventive Medicine, ADA American Diabetes Association, AGS American Geriatrics Society, APhA American Pharmacists Association, ASPC American Society for Preventive Cardiology, NLA National Lipid Association, PCNA Preventive Cardiovascular Nurses Association
If 10-year risk is ≥ 10%, an LDL-C ≥ 100 mg/dl is an indication for treatment. Age > 40 years with diabetes is an indication for treatment
LDL-C represented throughout table measured in mg/dl
If 10-year risk is ≥ 20%, no risk factors of LDL are required for treatment. Age ≥ 40 years with diabetes is an indication for treatment
Full title is 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. Age 40–75 years with diabetes or LDL-C ≥ 190 mg/dL is an indication for treatment
Full title is 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease. Age 40–75 years with diabetes, or age 20–75 years with LDL-C ≥ 190 mg/dL, is an indication for treatment
High-risk type of diabetes regardless of age is also an indication for treatment